CTMX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 17.16% compared to CytomX Therapeutics's net margin of -49.65%. CytomX Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

CytomX Therapeutics has a consensus price target of --, signalling upside risk potential of 384.95%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than CytomX Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than CytomX Therapeutics.

CytomX Therapeutics has a beta of 1.069, which suggesting that the stock is 6.902% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

CytomX Therapeutics quarterly revenues are $33.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. CytomX Therapeutics's net income of $5.7M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, CytomX Therapeutics's price-to-earnings ratio is 6.41x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.72x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 17.16% compared to CytomX Therapeutics's net margin of -2357.27%. CytomX Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

CytomX Therapeutics has a consensus price target of --, signalling upside risk potential of 384.95%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than CytomX Therapeutics, analysts believe Palatin Technologies is more attractive than CytomX Therapeutics.

CytomX Therapeutics has a beta of 1.069, which suggesting that the stock is 6.902% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

CytomX Therapeutics quarterly revenues are $33.4M, which are larger than Palatin Technologies quarterly revenues of $350K. CytomX Therapeutics's net income of $5.7M is higher than Palatin Technologies's net income of -$7.8M. Notably, CytomX Therapeutics's price-to-earnings ratio is 6.41x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.72x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of 17.16% compared to CytomX Therapeutics's net margin of -219.3%. CytomX Therapeutics's return on equity of -- beat Spero Therapeutics's return on equity of 4.36%.

CytomX Therapeutics has a consensus price target of --, signalling upside risk potential of 384.95%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 441.83%. Given that Spero Therapeutics has higher upside potential than CytomX Therapeutics, analysts believe Spero Therapeutics is more attractive than CytomX Therapeutics.

CytomX Therapeutics has a beta of 1.069, which suggesting that the stock is 6.902% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.892%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

CytomX Therapeutics quarterly revenues are $33.4M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. CytomX Therapeutics's net income of $5.7M is higher than Spero Therapeutics's net income of -$17.1M. Notably, CytomX Therapeutics's price-to-earnings ratio is 6.41x while Spero Therapeutics's PE ratio is 11.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.72x versus 0.55x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 17.16% compared to CytomX Therapeutics's net margin of --. CytomX Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

CytomX Therapeutics has a consensus price target of --, signalling upside risk potential of 384.95%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 6861.54%. Given that Theriva Biologics has higher upside potential than CytomX Therapeutics, analysts believe Theriva Biologics is more attractive than CytomX Therapeutics.

CytomX Therapeutics has a beta of 1.069, which suggesting that the stock is 6.902% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

CytomX Therapeutics quarterly revenues are $33.4M, which are larger than Theriva Biologics quarterly revenues of --. CytomX Therapeutics's net income of $5.7M is higher than Theriva Biologics's net income of -$7.7M. Notably, CytomX Therapeutics's price-to-earnings ratio is 6.41x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.72x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.